A Phase 3 interventional study of Fenofibrate/Simvastatin and Fenofibrate/Simvastatin in Hyperlipidemia, sponsored by Solvay Pharmaceuticals. Completed at 110 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-07-08.
Sponsored by Solvay Pharmaceuticals (part of Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing fenofibrate in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. Fenofibrate · Hyperlipidemias.
Among the 14 studies testing fenofibrate in Hyperlipidemias, this one has the largest enrollment, is one of 3 that started in 2005, is one of 7 in phase 3, and was the 6th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 14 studies testing fenofibrate in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
Fenofibrate: first FDA approval 1993 (TRICOR (MICRONIZED)), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 8 · Phase 4 4
First in 2004; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,040 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 178 across the 14 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under Solvay Pharmaceuticals, one of the names counted as Abbott. Under that name alone:
Solvay Pharmaceuticals is the lead sponsor of 86 studies on the registry; none are open to participants now.
Abbott has 6 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing fenofibrate in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to evaluate the efficacy and safety of combining fenofibrate and simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fenofibrate/Simvastatin
Drug: Fenofibrate/Simvastatin
Drug: Simvastatin
Drug pages: Fenofibrate · Simvastatin
Combination of Fenofibrate 145mg and Simvastatin 20mg
Drug pages: Fenofibrate · Simvastatin
Combination of Fenofibrate and Simvastatin 40 mg
Simvastatin 40 mg
Percent change from baseline to 24 weeks of treatment in Triglycerides
Time frame: 12 weeks
Percent change from baseline to 24 weeks of treatment in HDL-C
Time frame: 12 weeks
Percent change from baseline to 24 weeks of treatment in LDL-C
Time frame: 12 weeks
Percent change from baseline to 24 weeks of treatment in Triglycerides
Time frame: 24 weeks
Percent change from baseline to 24 weeks of treatment in HDL-C
Time frame: 24 weeks
Percent change from baseline to 24 weeks of treatment in LDL-C
Time frame: 24 weeks
Showing the first 100 of 110 sites across 8 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fenofibrate · Simvastatin